Last reviewed 2026-04-20 · How we verify

Solu-Medrol (methylprednisolone succinate)

At a glance

Approved indications

• Nephrotic syndrome

Common side effects

• Congestive heart failure
• Hypertension
• Thromboembolism
• Cardiac arrest
• Cardiac arrhythmias
• Circulatory collapse
• Fluid retention
• Hypokalemic alkalosis
• Potassium loss
• Sodium retention
• Peptic ulcer with possible perforation and hemorrhage
• Perforation of the small and large intestine

Key clinical trials

• Short-term Steroid Therapy in Patients With P. Jirovecii Pneumonia Due to HIV / AIDS (NA)
• Nivolumab in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma (PHASE3)
• Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia (PHASE2)
• A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Diagnosed B-Lymphoblastic Leukemia (PHASE3)
• Pulse Glucocorticoid Therapy in Patients With ST-Segment Elevation Myocardial Infarction (PHASE2)
• Brentuximab Vedotin and Combination Chemotherapy in Treating Children and Young Adults With Stage IIB, Stage IIIB, IVA, or IVB Hodgkin Lymphoma (PHASE3)
• OMT for Adhesive Capsulitis (PHASE4)
• Arthrosemid vs. Steroid for the Management Knee Osteoarthritis (PHASE4)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• Solu-Medrol CI brief — competitive landscape report
• Solu-Medrol updates RSS · CI watch RSS
• Pfizer portfolio CI